It’s only fair to share… Navepdekinra CAS 2467732-66-5 MF C33H48FN7O4 MW625.78 1H-Pyrazole-5-carboxamide, 1-ethyl-N-[(1S)-2-[[2-fluoro-4-[(1S,2R)-1-methyl-3-(4-methyl-1-piperazinyl)-3-oxo-2-[(1-oxopropyl)amino]propyl]phenyl]amino]-1-(trans-4-methylcyclohexyl)-2-oxoethyl]- 1-ethyl-N-{(1S)-2-{2-fluoro-4-[(2S,3R)-4-(4-methylpiperazin-1-yl)-4-oxo-3-propanamidobutan-2-yl]anilino}-1-[(1r,4S)-4-methylcyclohexyl]-2-oxoethyl}-1H-pyrazole-5-carboxamide 1-ethyl-N-{(1S)-2-{2-fluoro-4-[(2S,3R)-4-(4-methylpiperazin-1-yl)-4-oxo-3-propanamidobutan-2-yl]anilino}-1-[(1r,4S)-4-methylcyclohexyl]-2-oxoethyl}-1H-pyrazole-5-carboxamideinterleukin-17A (IL-17A) inhibitor, anti-inflammatory, DC-806, LY4100504, DC 806, LY 4100504, Y64F9MC2QM Navepdekinra (also known as DC-806 or LY4100504) is an experimental, orally active small-molecule inhibitor of interleukin-17A (IL-17A). It was primarily developed to treat autoimmune and inflammatory conditions, such as psoriasis, by disrupting the interaction between IL-17A and …
Category «Uncategorized»
Napazimone
It’s only fair to share… Napazimone CAS 1800405-30-4 MF C14H12N2O2 MW240.26 g/mol 2-(propan-2-yl)-1H-naphtho[1,2-d]imidazole-4,5-dioneNAD(P)H dehydrogenase [quinone] 1 (NQO1) activator, KL 1333, KL-1333, NA2ZOL5UGM Napazimone (also known as KL1333) is an investigational small molecule drug currently being developed for the treatment of primary mitochondrial disease. It is an orally available modulator that aims to improve energy production in patients with rare genetic …
Nacresertib
It’s only fair to share… Nacresertib CAS 2629977-59-7 MF C22H26N4O4, 410.5 g/mol N-[2-(4-hydroxy-4-methylcyclohexyl)-6-methoxyindazol-5-yl]-6-methyl-1-oxidopyridin-1-ium-2-carboxamide 2-({2-[(1r,4r)-4-hydroxy-4-methylcyclohexyl]-6-methoxy-2H-indazol-5-yl}carbamoyl)-6-methylpyridine1-oxideserine/threonine kinase inhibitor, MB3QBD4BE7, SYN compound 001 [WO2021057785] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021057785&_cid=P20-MLN614-09477-1 Example 1: Synthesis of Compound 001 ynthesis of compound 001, namely 2-((2-(trans-4-hydroxy-cis-4-methylcyclohexyl)-6-methoxy-2H-indazol-5-yl)carbamoyl)-6-methylpyridine 1-oxide [0133] [0134]Cesium carbonate (985 mg) was added to 5 mL of a DMF solution containing compound 12 (300 mg) and compound 5 …
Mosperafenib
It’s only fair to share… Mosperafenib CAS 2649372-20-1 MF C20H17F2N5O4S MW 461.4 g/mol (3R)-N-{2-cyano-4-fluoro-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-3-fluoropyrrolidine-1-sulfonamideB-Raf (BRAF) inhibitor, antineoplastic, RG6344, RO7276389, RG 6344, RO 7276389, 881-730-4, B-Raf IN 2 Mosperafenib is a small molecule drug. The usage of the INN stem ‘-rafenib’ in the name indicates that Mosperafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Mosperafenib has …
Mocaciclib
It’s only fair to share… Mocaciclib CAS 2766124-39-2 MF C33H36FN9O2 MW609.71 cyclin-dependent kinase (CDK) inhibitor, antineoplastic, Q 901, CDK7-IN-21, Mocaciclib (Q-901) is an orally bioavailable, selective cyclin-dependent kinase (CDK) inhibitor with potent activity against CDK2, CDK4, and CDK6. Preclinical data show that Mocaciclib inhibits CDK2/cyclin E with an IC₅₀ of 1.1 nM, CDK4/cyclin D1 with …
Mobinitinib
It’s only fair to share… Mobinitinib CAS1402709-93-6 MF C22H23Cl2N7 MW456.37 6-chloro-7-{4-[(4-chlorophenyl)methyl]piperazin-1-yl}-2-(1,3-dimethyl-1Hpyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 6-chloro-7-{4-[(4-chlorophenyl)methyl]piperazin-1-yl}-2-(1,3-dimethyl-1Hpyrazol-4-yl)-3H-imidazo[4,5-b]pyridinedual FMS-like tyrosine kinase-3 (FLT3)-Aurora kinase inhibitor, antineoplastic, CCT241736, CCT 241736, ZE94SP78UG, EP0042, EP 0042 Mobinitinib (CCT241736) is an investigational, orally bioavailable, small-molecule, dual inhibitor targeting Aurora kinase and FLT3 (including ITD and D835Y mutations). It shows potent antineoplastic activity in preclinical models, including acute myeloid …
Mevrometostat
It’s only fair to share… Mevrometostat CAS 1844849-10-0 MF C22H24Cl2N2O5 MW467.3 g/mol 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one 5,8-dichloro-7-[(R)-methoxy(oxetan-3-yl)methyl]-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-oneenhancer of zeste homolog 2 (EZH2) inhibitor, antineoplastic, PF-06821497, PF 06821497, S4L4MM20B6 Mevrometostat (development code PF-06821497) is an investigational anticancer drug that functions as a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2).[1][2] Currently under development by Pfizer, mevrometostat is being investigated primarily for the treatment …
Maritupirdine
It’s only fair to share… Maritupirdine CAS 1025725-91-0 MF C21H24N2 MW304.4 g/mol 2,3,4,5-TETRAHYDRO-2,8-DIMETHYL-5-PHENETHYL-1H-PYRIDO(4,3-B)INDOLE 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoleserotonin receptor antagonist, antidepressant, AVN-101, AVN 101, CD 008 0045, 6MHR5IV28S MARITUPIRDINE is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Maritupirdine (developmental code name AVN-101), a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by …
Luvometinib
It’s only fair to share… Luvometinib CAS 2739690-43-6 MF C26H22F2IN5O4S MW665.5 g/mol CHINA 2025, APPROVALS 2025 N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide N-{3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl]phenyl}cyclopropanesulfonamidemitogen-activated protein kinase (MEK) inhibitor, antineoplastic, FCN 159, FCN-159, B2DYT4V89X Luvometinib is a drug for the treatment of various types of cancer. It is a selective, orally administered inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/MEK2), developed by Fosun Pharma for the …
Lutetium (177Lu) tezuvotide tetraxetan
It’s only fair to share… Lutetium (177Lu) tezuvotide tetraxetan CAS2613239-73-7 MF C60H92F177LuN12O23Si , 1573.5 g/mol 2-[4-[2-[[(2R)-1-[[(1R)-1-carboxy-5-[[4-[[(4R)-4-carboxy-4-[[(4S)-4-carboxy-4-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]butanoyl]amino]butyl]amino]-4-oxobutanoyl]amino]pentyl]amino]-3-[[4-[ditert-butyl(fluoro)silyl]benzoyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) antineoplastic, 177LU-RHPSMA-10.1, RHPSMA-10.1 LUTETIUM LU-177, FJ9Z7Y8MRW Lutetium (177Lu) tezuvotide tetraxetan ($^{177}$Lu-rhPSMA-10.1) is an experimental radioligand therapy, developed by Bracco, that targets prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer. It uses a radiohybrid (rh) PSMA molecule, designed to have high …